DISRUPT THE
SIGNAL
WITH JAK INHIBITION

For the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis (AD) whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable.1

RINVOQ modulates cytokine signaling by inhibiting JAK. By modulating these signals, RINVOQ modulates cytokine signaling to help reduce inflammation.1

Pathway
Inhibition

Dialing down AD inflammation via the JAK-STAT pathway1-5

Overexpression of these 6 cytokines can lead to chronic inflammation and may contribute to AD signs and symptoms such as itching, skin barrier dysfunction, and epidermal hyperplasia.

The clinical impact of these pathways on patients with AD is not fully understood.

Dialing down AD inflammation via the JAK-STAT pathway

<<Swipe image to see more

The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness and safety is not currently known.

Patient Image

The clinical impact of these pathways on patients with AD is not fully understood.

The proinflammatory cytokines shown here signal through the JAK-STAT pathway, a key downstream signaling pathway. Many cytokines are thought to signal through pairs of JAKs (JAK1/JAK2, JAK1/JAK3, JAK1/TYK2, JAK2/JAK2, JAK2/TYK2).1-4

Th2, Th22, and TH1 cytokines shown are not exhaustive; other cytokines in the Th2, Th22, and Th1 classes are not shown.

ATP=adenosine triphosphate; IFN=interferon; IL=interleukin; JAK=Janus kinase; STAT=signal transducer and activator of transcription; Th=T healer cell; TSLP=thymic lymphopoietin; TYK=tyrosine kinase.

RINVOQ modulates the signaling by inhibiting JAK1,2,6,7

The relevance of inhibition of specific JAK enzymes to therapeutic effectiveness and safety is not currently known.

<<Swipe image to see more

RINVOQ leverages the structural differences within the JAK family ATP binding site, enabling preferential binding.
Based on enzymatic and cellular assays, RINVOQ exhibits greater inhibitory potency at JAK1 and JAK2 compared to JAK3 and TYK2.1,6

RINVOQ Inhibitory Potency

ATP=adenosine triphosphate; IFN=interferon; IL=interleukin; JAK=Janus kinase; STAT=signal transducer and activator of transcription; TSLP=thymic lymphopoietin; TYK=tyrosine kinase.